Cdki-73 (LS-007) is an orally active and highly effective CDK9 inhibitor with Ki values of 4 nM, 4 nM and 3 nM against CDK9, CDK1 and CDK2, respectively. Cdki-73 down-regulates phosphorylation of RNA polymerase II. Cdki-73 is also an inhibitor of Rab11.
GsMTx4 is a spider venom peptide that selectively inhibits cation-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families.
GsMTx4 is a spider venom peptide that selectively inhibits cation-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families.
Calcitonin is a single-chain polypeptide composed of 32 amino acid residues, the major physiological effects of calcitonin are inhibition of bone resorption and deposition of postabsorptive calcium into bone following a meal, which prevents postprandial hypercalcemia.
Calcitonin is a single-chain polypeptide composed of 32 amino acid residues, the major physiological effects of calcitonin are inhibition of bone resorption and deposition of postabsorptive calcium into bone following a meal, which prevents postprandial hypercalcemia.
Plecanatide is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist.
Plecanatide is a structural analog of human uroguanylin, and similarly to uroguanylin, plecanatide functions as a guanylate cyclase-C (GC-C) agonist.
USP7-IN-8 is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in the Ub-Rho110 assay.USP7-IN-8 is inactive against USP47 and USP5.USP7-IN-8 has anticancer effects.
USP7-IN-8 is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in the Ub-Rho110 assay.USP7-IN-8 is inactive against USP47 and USP5.USP7-IN-8 has anticancer effects.
Glycohyodeoxycholic acid is the main metabolite of Hyodeoxycholic acid in human body, which can prevent the formation of gallstones.
Glycohyodeoxycholic acid is the main metabolite of Hyodeoxycholic acid in human body, which can prevent the formation of gallstones.
Valbenazine (NBI-98854) is a vesicular monoamine transporter-2 (VMAT2) inhibitor with a Ki of 110-190 nM.